Corcept Therapeutics (NASDAQ:CORT) Stock Down...But Not Out

462 0 0 0 0 0 (0)

Corcept Therapeutics Incorporated (NASDAQ:CORT) stock has been down in reaction to the FDA's approval for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)'s generic version of mifepristone, the active ingredient in Corcept's Korlym and its sole commercially available product. Mifepristone or RU-486, is used in combination with misoprostol, to bring about an abortion. This combination is more than 95% effective during the first 50 days of pregnancy.

However, recently the FDA granted orphan drug status for Corcept Therapeutics Incorporated (NASDAQ:CORT)'s relacorilant, which is used to treat patients with pancreatic cancer. Drugs that receive orphan status obtain seven years of marketing exclusivity from the date of drug approval, tax credits for clinical trial costs, marketing application filing fee waivers and assistance from the FDA in the drug development process. 

Register now for the world's best investment ideas


The company report earnings on Nov 8th and we look for in-line or a beat as CORT Stock has been slowly moving up over the last few months on the Hade Platform investment-grade scale. In fact, Corcept Therapeutics Incorporated (NASDAQ: CORT) stock has risen into the Top 30.  Ironically, this stability in overall rating happens during a time when the overall market is falling, and as our investment grades as an average have consistently declined for the last four months, effectively predicting a correction.

With overall investment grades still lower, we suggest holding large sums of cash and being very selective when making investment decisions. According to CORT stock’s current grade, it might very well be one of those selective opportunities. Why should you trust our ratings? The Hade Platform has proven over the course of three years through the application of DLAs and artificial intelligence that it consistently outperforms Wall Street consensus estimates (63%) and major benchmarks such as the S&P 500 (250%). Access our premium services and start beating the market. 

Comments (0)

Recent Updates

  •   
    Mar 6, 2019 11:15 PM

    DENTSPLY SIRONA Inc - Consumables Revenue

  •   
    Mar 6, 2019 11:15 PM

    DENTSPLY SIRONA Inc - Europe Revenue

  •   
    Mar 6, 2019 11:15 PM

    DENTSPLY SIRONA Inc - United States Revenue

  •   
    Mar 6, 2019 11:15 PM

    DENTSPLY SIRONA Inc - Rest of World Revenue

  •   
    Mar 6, 2019 11:15 PM

    DENTSPLY SIRONA Inc - Technologies and Equipment Total Net Sales ex. PM sales Revenue

  •   
    Mar 6, 2019 11:15 PM

    DENTSPLY SIRONA Inc - Technologies and Equipment Revenue